PLN-74809, an oral treatment candidate for idiopathic pulmonary fibrosis (IPF), will now be called bexotegrast, its maker, Pliant Therapeutics, announced in a corporate update. The change came after the International Nonproprietary Names Expert Group selected bexotegrast as the unique generic, or nonproprietary, name for the experimental therapy. The company also announced…
Being short of breath is the worst feeling I’ve ever experienced. Sadly, it’s been getting progressively worse since I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2016. Shortness of breath, or dyspnea, is one of the most common IPF symptoms. It took 13 months of seeing…
Rail travel has long been shrouded in both mystery and romance. English novelist Agatha Christie famously wrote “Murder on the Orient Express,” a tale of intrigue involving one of her most famous characters, Hercule Poirot. American singer-songwriter Steve Goodman originally wrote and recorded “City of New Orleans,” a song about…
Bridge Biotherapeutics has launched a Phase 2a clinical trial to assess the safety, tolerability, and effectiveness of BBT-877 in people with idiopathic pulmonary fibrosis (IPF). The trial (NCT05483907) is expected to enroll around 120 IPF patients, ages 40 and older, in 50 clinical sites in North America,…
For all the time I’ve spent in my 31 years “sitting in the U-bend, thinking about death,” as Moaning Myrtle from the “Harry Potter” series says, facing the loss of a loved one hasn’t gotten any easier. In spite of all my pondering, reading, and writing on the subject of…
The Pulmonary Fibrosis Foundation (PFF) is welcoming applications for its 2023 PFF Scholars program, which helps fund early-stage investigators developing research to improve the outcomes of people with pulmonary fibrosis (PF). Each investigator will receive a two-year research grant totaling $100,000, which is an increase of $25,000 a scholar…
Navigating the healthcare system on a regular basis can be draining. This is especially true considering that many hospitals, acute care clinics, and family physicians are struggling to deal with a backlog of patients in the wake of the COVID-19 pandemic. Unfortunately, the U.S. Centers for Disease Control and Prevention…
Following the successful completion of preclinical studies, Saniona is now ready to initiate the regulatory process needed to start testing SAN903 — its therapy candidate for idiopathic pulmonary fibrosis (IPF) and other disorders — in Phase 1 human trials. “Preclinical data for SAN903 are very compelling,” Thomas Feldthus,…
Idiopathic pulmonary fibrosis (IPF) patients often require a multidisciplinary team to manage their care. My IPF journey has been shaped by all the medical professionals I’ve encountered along the way. I was formally diagnosed on Jan. 31, 2017, at the Inova Fairfax Hospital’s Advanced Lung Disease and Transplant…
Real-world data support the safety profile of the anti-fibrotic medications Esbriet (pirfenidone) and Ofev (nintedanib) in people with idiopathic pulmonary fibrosis (IPF), according to a new study. More than half of patients experienced treatment-related adverse events, the majority being non-severe gastrointestinal symptoms. Rare cases of serious heart-related…
Get regular updates to your inbox.
